Abstract
Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer-related death in the United States, with 43,000 deaths per year and a dismal overall 5-year survival rate of only 8%. Early diagnosis and management planning is therefore essential for optimal clinical outcomes in these patients, as survival is largely dependent on cancer stage, with a 5-year survival rate of 29% for localized disease compared with only 3% for metastatic disease. Endoscopic ultrasound (EUS) combined with fine-needle aspiration (FNA) is the most accurate modality available for the diagnosis of pancreatic cancer and has thus resulted in a paradigm shift in the management of these patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
